{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:40:50Z","timestamp":1790656850557,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"34","license":[{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["16K09872"],"award-info":[{"award-number":["16K09872"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["16K09872"],"award-info":[{"award-number":["16K09872"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K17829"],"award-info":[{"award-number":["19K17829"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["16K09872"],"award-info":[{"award-number":["16K09872"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["16K09872"],"award-info":[{"award-number":["16K09872"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2020,8,20]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The family of signal-transducing adapter proteins (STAPs) has been reported to be involved in a variety of intracellular signaling pathways and implicated as transcriptional factors. We previously cloned STAP-2 as a c-Fms interacting protein and explored its effects on chronic myeloid leukemia (CML) leukemogenesis. STAP-2 binds to BCR-ABL, upregulates BCR-ABL phosphorylation, and activates its downstream molecules. In this study, we evaluated the role of STAP-1, another member of the STAP family, in CML pathogenesis. We found that the expression of STAP-1 is aberrantly upregulated in CML stem cells (LSCs) in patients\u2019 bone marrow. Using experimental model mice, deletion of STAP-1 prolonged the survival of CML mice with inducing apoptosis of LSCs. The impaired phosphorylation status of STAT5 by STAP-1 ablation leads to downregulation of antiapoptotic genes, Bcl-2 and Bcl-xL. Interestingly, transcriptome analyses indicated that STAP-1 affects several signaling pathways related to BCR-ABL, JAK2, and PPAR\u03b3. This adapter protein directly binds to not only BCR-ABL, but also STAT5 proteins, showing synergistic effects of STAP-1 inhibition and BCR-ABL or JAK2 tyrosine kinase inhibition. Our results identified STAP-1 as a regulator of CML LSCs and suggested it to be a potential therapeutic target for CML.<\/jats:p>","DOI":"10.1038\/s41388-020-01387-9","type":"journal-article","created":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T13:04:55Z","timestamp":1594645495000},"page":"5601-5615","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Signal-transducing adapter protein-1 is required for maintenance of leukemic stem cells in CML"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0297-5640","authenticated-orcid":false,"given":"Jun","family":"Toda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0018-6656","authenticated-orcid":false,"given":"Michiko","family":"Ichii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Oritani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4014-2815","authenticated-orcid":false,"given":"Hirohiko","family":"Shibayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Tanimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Motooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4552-783X","authenticated-orcid":false,"given":"Daisuke","family":"Okuzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Kitai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7474-493X","authenticated-orcid":false,"given":"Ryuta","family":"Muromoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7863-6696","authenticated-orcid":false,"given":"Jun-ichi","family":"Kashiwakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzuru","family":"Kanakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,13]]},"reference":[{"key":"1387_CR1","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nrc1567","volume":"5","author":"R Ren","year":"2005","unstructured":"Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5:172\u201383.","journal-title":"Nat Rev Cancer"},{"key":"1387_CR2","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","volume":"113","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009;113:1619\u201330.","journal-title":"Blood"},{"key":"1387_CR3","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, R\u00e9a D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029\u201335.","journal-title":"Lancet Oncol"},{"key":"1387_CR4","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122:515\u201322.","journal-title":"Blood"},{"key":"1387_CR5","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19:747\u201357.","journal-title":"Lancet Oncol"},{"key":"1387_CR6","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood.V99.1.319","volume":"99","author":"SM Graham","year":"2002","unstructured":"Graham SM, J\u00f8rgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99:319\u201325.","journal-title":"Blood"},{"key":"1387_CR7","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","volume":"107","author":"M Copland","year":"2006","unstructured":"Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006;107:4532\u20139.","journal-title":"Blood"},{"key":"1387_CR8","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1182\/blood-2008-08-176016","volume":"114","author":"RM Lemoli","year":"2009","unstructured":"Lemoli RM, Salvestrini V, Bianchi E, Bertolini F, Fogli M, Amabile M, et al. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. Blood. 2009;114:5191\u2013200.","journal-title":"Blood"},{"key":"1387_CR9","doi-asserted-by":"publisher","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","volume":"118","author":"S Chu","year":"2011","unstructured":"Chu S, McDonald T, Lin A, Chakraborty S, Huang Q, Snyder DS, et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood. 2011;118:5565\u201372.","journal-title":"Blood"},{"key":"1387_CR10","doi-asserted-by":"publisher","first-page":"35293","DOI":"10.18632\/oncotarget.9182","volume":"7","author":"JC Chomel","year":"2016","unstructured":"Chomel JC, Bonnet ML, Sorel N, Sloma I, Bennaceur-Griscelli A, Rea D, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation. Oncotarget. 2016;7:35293\u2013301.","journal-title":"Oncotarget"},{"key":"1387_CR11","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1038\/leu.2010.185","volume":"24","author":"DM Ross","year":"2010","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Bartley PA, et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia. 2010;24:1719\u201324.","journal-title":"Leukemia"},{"key":"1387_CR12","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nm.4336","volume":"23","author":"A Giustacchini","year":"2017","unstructured":"Giustacchini A, Thongjuea S, Barkas N, Woll PS, Povinelli BJ, Booth CAG, et al. Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia. Nat Med. 2017;23:692\u2013702.","journal-title":"Nat Med"},{"key":"1387_CR13","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1182\/blood-2016-07-728873","volume":"129","author":"R Warfvinge","year":"2017","unstructured":"Warfvinge R, Geironson L, Sommarin MNE, Lang S, Karlsson C, Roschupkina T, et al. Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML. Blood. 2017;129:2384\u201394.","journal-title":"Blood"},{"key":"1387_CR14","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"AS Corbin","year":"2011","unstructured":"Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011;121:396\u2013409.","journal-title":"J Clin Invest"},{"key":"1387_CR15","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","volume":"119","author":"A Hamilton","year":"2012","unstructured":"Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood. 2012;119:1501\u201310.","journal-title":"Blood"},{"key":"1387_CR16","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nature08734","volume":"463","author":"K Naka","year":"2010","unstructured":"Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, Kondo Y, et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature. 2010;463:676\u201380.","journal-title":"Nature"},{"key":"1387_CR17","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","volume":"12","author":"C Zhao","year":"2007","unstructured":"Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM, et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell. 2007;12:528\u201341.","journal-title":"Cancer Cell"},{"key":"1387_CR18","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/nature07737","volume":"458","author":"C Zhao","year":"2009","unstructured":"Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson A, Blum J, et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature. 2009;458:776\u20139.","journal-title":"Nature"},{"key":"1387_CR19","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1182\/blood-2006-08-040022","volume":"109","author":"Y Wang","year":"2007","unstructured":"Wang Y, Cai D, Brendel C, Barett C, Erben P, Manley PW, et al. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR\/ABL+ progenitors via JAK-2\/STAT-5 pathway activation. Blood. 2007;109:2147\u201355.","journal-title":"Blood"},{"key":"1387_CR20","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1038\/leu.2017.108","volume":"31","author":"X Liu","year":"2017","unstructured":"Liu X, Rothe K, Yen R, Fruhstorfer C, Maetzig T, Chen M, et al. A novel AHI-1-BCR-ABL-DNM2 complex regulates leukemic properties of primitive CML cells through enhanced cellular endocytosis and ROS-mediated autophagy. Leukemia. 2017;31:2376\u201387.","journal-title":"Leukemia"},{"key":"1387_CR21","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1182\/blood-2013-12-545640","volume":"124","author":"P Gallipoli","year":"2014","unstructured":"Gallipoli P, Cook A, Rhodes S, Hopcroft L, Wheadon H, Whetton AD, et al. JAK2\/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. Blood. 2014;124:1492\u2013501.","journal-title":"Blood"},{"key":"1387_CR22","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1182\/blood-2013-02-485607","volume":"122","author":"P Gallipoli","year":"2013","unstructured":"Gallipoli P, Pellicano F, Morrison H, Laidlaw K, Allan EK, Bhatia R, et al. Autocrine TNF-\u03b1 production supports CML stem and progenitor cell survival and enhances their proliferation. Blood. 2013;122:3335\u20139.","journal-title":"Blood"},{"key":"1387_CR23","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1182\/blood-2015-11-679985","volume":"128","author":"H \u00c5gerstam","year":"2016","unstructured":"\u00c5gerstam H, Hansen N, von Palffy S, Sand\u00e9n C, Reckzeh K, Karlsson C, et al. IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models. Blood. 2016;128:2683\u201393.","journal-title":"Blood"},{"key":"1387_CR24","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.ccr.2011.10.012","volume":"20","author":"D Reynaud","year":"2011","unstructured":"Reynaud D, Pietras E, Barry-Holson K, Mir A, Binnewies M, Jeanne M, et al. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell. 2011;20:661\u201373.","journal-title":"Cancer Cell"},{"key":"1387_CR25","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nature15248","volume":"525","author":"S Prost","year":"2015","unstructured":"Prost S, Relouzat F, Spentchian M, Ouzegdouh Y, Saliba J, Massonnet G, et al. Erosion of the chronic myeloid leukaemia stem cell pool by PPAR\u03b3 agonists. Nature. 2015;525:380\u20133.","journal-title":"Nature"},{"key":"1387_CR26","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ccr.2012.02.018","volume":"21","author":"B Zhang","year":"2012","unstructured":"Zhang B, Ho YW, Huang Q, Maeda T, Lin A, Lee SU, et al. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell. 2012;21:577\u201392.","journal-title":"Cancer Cell"},{"key":"1387_CR27","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.stem.2019.02.018","volume":"24","author":"P Agarwal","year":"2019","unstructured":"Agarwal P, Isringhausen S, Li H, Paterson AJ, He J, Gomariz \u00c1, et al. Mesenchymal niche-specific expression of Cxcl12 controls quiescence of treatment-resistant leukemia stem cells. Cell Stem Cell. 2019;24:769.","journal-title":"Cell Stem Cell"},{"key":"1387_CR28","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1006\/bbrc.2000.2223","volume":"268","author":"M Masuhara","year":"2000","unstructured":"Masuhara M, Nagao K, Nishikawa M, Sasaki M, Yoshimura A, Osawa M. Molecular cloning of murine STAP-1, the stem-cell-specific adaptor protein containing PH and SH2 domains. Biochem Biophys Res Commun. 2000;268:697\u2013703.","journal-title":"Biochem Biophys Res Commun"},{"key":"1387_CR29","doi-asserted-by":"publisher","first-page":"11182","DOI":"10.1074\/jbc.M211230200","volume":"278","author":"M Minoguchi","year":"2003","unstructured":"Minoguchi M, Minoguchi S, Aki D, Joo A, Yamamoto T, Yumioka T, et al. STAP-2\/BKS, an adaptor\/docking protein, modulates STAT3 activation in acute-phase response through its YXXQ motif. J Biol Chem. 2003;278:11182\u20139.","journal-title":"J Biol Chem"},{"key":"1387_CR30","doi-asserted-by":"publisher","first-page":"8188","DOI":"10.1074\/jbc.M411692200","volume":"280","author":"Y Sekine","year":"2005","unstructured":"Sekine Y, Yamamoto T, Yumioka T, Sugiyama K, Tsuji S, Oritani K, et al. Physical and functional interactions between STAP-2\/BKS and STAT5. J Biol Chem. 2005;280:8188\u201396.","journal-title":"J Biol Chem"},{"key":"1387_CR31","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/j.1349-7006.2010.01842.x","volume":"102","author":"O Ikeda","year":"2011","unstructured":"Ikeda O, Mizushima A, Sekine Y, Yamamoto C, Muromoto R, Nanbo A, et al. Involvement of STAP-2 in Brk-mediated phosphorylation and activation of STAT5 in breast cancer cells. Cancer Sci. 2011;102:756\u201361.","journal-title":"Cancer Sci"},{"key":"1387_CR32","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1038\/onc.2011.604","volume":"31","author":"Y Sekine","year":"2012","unstructured":"Sekine Y, Ikeda O, Mizushima A, Ueno Y, Muromoto R, Yoshimura A, et al. STAP-2 interacts with and modulates BCR-ABL-mediated tumorigenesis. Oncogene. 2012;31:4384\u201396.","journal-title":"Oncogene"},{"key":"1387_CR33","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/sj.leu.2404549","volume":"21","author":"E Diaz-Blanco","year":"2007","unstructured":"Diaz-Blanco E, Bruns I, Neumann F, Fischer JC, Graef T, Rosskopf M, et al. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia. 2007;21:494\u2013504.","journal-title":"Leukemia"},{"key":"1387_CR34","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/eji.201344239","volume":"44","author":"N Fujita","year":"2014","unstructured":"Fujita N, Oritani K, Ichii M, Yokota T, Saitoh N, Okuzaki D, et al. Signal-transducing adaptor protein-2 regulates macrophage migration into inflammatory sites during dextran sodium sulfate induced colitis. Eur J Immunol. 2014;44:1791\u2013801.","journal-title":"Eur J Immunol"},{"key":"1387_CR35","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nature18288","volume":"534","author":"SA Abraham","year":"2016","unstructured":"Abraham SA, Hopcroft LE, Carrick E, Drotar ME, Dunn K, Williamson AJ, et al. Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. Nature. 2016;534:341\u20136.","journal-title":"Nature"},{"key":"1387_CR36","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1182\/blood-2011-10-387381","volume":"119","author":"H Zhang","year":"2012","unstructured":"Zhang H, Li H, Xi HS, Li S. HIF1\u03b1 is required for survival maintenance of chronic myeloid leukemia stem cells. Blood. 2012;119:2595\u2013607.","journal-title":"Blood"},{"key":"1387_CR37","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1084\/jem.20110304","volume":"208","author":"C Hurtz","year":"2011","unstructured":"Hurtz C, Hatzi K, Cerchietti L, Braig M, Park E, Kim YM, et al. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med. 2011;208:2163\u201374.","journal-title":"J Exp Med"},{"key":"1387_CR38","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.leukres.2018.10.002","volume":"74","author":"K Sweet","year":"2018","unstructured":"Sweet K, Hazlehurst L, Sahakian E, Powers J, Nodzon L, Kayali F, et al. A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease. Leuk Res. 2018;74:89\u201396.","journal-title":"Leuk Res"},{"key":"1387_CR39","doi-asserted-by":"publisher","first-page":"11976","DOI":"10.1073\/pnas.96.21.11976","volume":"96","author":"K Ohya","year":"1999","unstructured":"Ohya K, Kajigaya S, Kitanaka A, Yoshida K, Miyazato A, Yamashita Y, et al. Molecular cloning of a docking protein, BRDG1, that acts downstream of the Tec tyrosine kinase. Proc Natl Acad Sci USA. 1999;96:11976\u201381.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1387_CR40","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.1038\/sj.onc.1203775","volume":"19","author":"PJ Mitchell","year":"2000","unstructured":"Mitchell PJ, Sara EA, Crompton MR. A novel adaptor-like protein which is a substrate for the non-receptor tyrosine kinase, BRK. Oncogene. 2000;19:4273\u201382.","journal-title":"Oncogene"},{"key":"1387_CR41","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.bbrc.2008.12.021","volume":"379","author":"K Stoecker","year":"2009","unstructured":"Stoecker K, Weigelt K, Ebert S, Karlstetter M, Walczak Y, Langmann T. Induction of STAP-1 promotes neurotoxic activation of microglia. Biochem Biophys Res Commun. 2009;379:121\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"1387_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17704-4","volume":"8","author":"EMP Steeghs","year":"2018","unstructured":"Steeghs EMP, Bakker M, Hoogkamer AQ, Boer JM, Hartman QJ, Stalpers F, et al. High STAP1 expression in DUX4-rearranged cases is not suitable as therapeutic target in pediatric B-cell precursor acute lymphoblastic leukemia. Sci Rep. 2018;8:693.","journal-title":"Sci Rep"},{"key":"1387_CR43","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1084\/jem.189.8.1229","volume":"189","author":"M Nieborowska-Skorska","year":"1999","unstructured":"Nieborowska-Skorska M, Wasik MA, Slupianek A, Salomoni P, Kitamura T, Calabretta B, et al. Signal transducer and activator of transcription (STAT)5 activation by BCR\/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR\/ABL and is required for leukemogenesis. J Exp Med. 1999;189:1229\u201342.","journal-title":"J Exp Med"},{"key":"1387_CR44","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1182\/blood.V95.6.2118","volume":"95","author":"C Sillaber","year":"2000","unstructured":"Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD. STAT5 activation contributes to growth and viability in Bcr\/Abl-transformed cells. Blood. 2000;95:2118\u201325.","journal-title":"Blood"},{"key":"1387_CR45","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/emmm.201000062","volume":"2","author":"A Hoelbl","year":"2010","unstructured":"Hoelbl A, Schuster C, Kovacic B, Zhu B, Wickre M, Hoelzl MA, et al. Stat5 is indispensable for the maintenance of bcr\/abl-positive leukaemia. EMBO Mol Med. 2010;2:98\u2013110.","journal-title":"EMBO Mol Med"},{"key":"1387_CR46","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.18632\/oncotarget.806","volume":"3","author":"W Warsch","year":"2012","unstructured":"Warsch W, Grundschober E, Berger A, Gille L, Cerny-Reiterer S, Tigan AS, et al. STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia. Oncotarget. 2012;3:1669\u201387.","journal-title":"Oncotarget"},{"key":"1387_CR47","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1182\/blood-2009-11-255232","volume":"117","author":"EA Nelson","year":"2011","unstructured":"Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB, et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011;117:3421\u20139.","journal-title":"Blood"},{"key":"1387_CR48","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1182\/blood-2002-05-1324","volume":"100","author":"X Jiang","year":"2002","unstructured":"Jiang X, Ng E, Yip C, Eisterer W, Chalandon Y, Stuible M, et al. Primitive interleukin 3 null hematopoietic cells transduced with BCR-ABL show accelerated loss after culture of factor-independence in vitro and leukemogenic activity in vivo. Blood. 2002;100:3731\u201340.","journal-title":"Blood"},{"key":"1387_CR49","doi-asserted-by":"publisher","first-page":"31774","DOI":"10.1074\/jbc.M110.118653","volume":"285","author":"M Tokunaga","year":"2010","unstructured":"Tokunaga M, Ezoe S, Tanaka H, Satoh Y, Fukushima K, Matsui K, et al. BCR-ABL but not JAK2 V617F inhibits erythropoiesis through the Ras signal by inducing p21CIP1\/WAF1. J Biol Chem. 2010;285:31774\u201382.","journal-title":"J Biol Chem"},{"key":"1387_CR50","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.omtm.2019.01.005","volume":"13","author":"N Uchida","year":"2019","unstructured":"Uchida N, Nassehi T, Drysdale CM, Gamer J, Yapundich M, Demirci S, et al. High-efficiency lentiviral transduction of human CD34. Mol Ther Methods Clin Dev. 2019;13:187\u201396.","journal-title":"Mol Ther Methods Clin Dev"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-020-01387-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-020-01387-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-020-01387-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T19:05:59Z","timestamp":1650222359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-020-01387-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,13]]},"references-count":50,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2020,8,20]]}},"alternative-id":["1387"],"URL":"https:\/\/doi.org\/10.1038\/s41388-020-01387-9","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,13]]},"assertion":[{"value":"21 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}